Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

769
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer - a review of current evidence and perspectives.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Cardiac metastasis of urothelial carcinoma mimicking ST-elevation myocardial infarction.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Analysis of progression of number and structure of scans performed using PET, PET/ CT and PET/ MRI in the Czech Republic in 2013- 2021.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024
Same author

Retroperitoneal tumour resection in fifteen consecutive cases: Single centre experience.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2023

Related Experiment Video

Updated: Mar 29, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

[Immunotherapy for Renal Cell Carcinoma].

T Büchler

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |December 10, 2015
    PubMed
    Summary

    Immunotherapy shows promise for advanced renal cell carcinoma, offering new hope beyond traditional treatments. Ongoing studies with checkpoint inhibitors like PD-1 antibodies are exploring its full potential.

    Area of Science:

    • Oncology
    • Immunology

    Context:

    • Renal cell carcinoma (RCC) exhibits resistance to chemotherapy and radiotherapy.
    • Current systemic therapies for RCC include anti-angiogenic and intracellular signaling inhibitors.
    • Emerging immunotherapeutic strategies are demonstrating significant potential in treating RCC.

    Purpose:

    • To review the evolution of immunotherapy for renal cell carcinoma (RCC).
    • To analyze published study results of novel immunotherapeutic agents, focusing on checkpoint inhibitors.

    Summary:

    • Nonspecific immunotherapy has historically induced long-term remission in a subset of RCC patients.
    • Advances in immunology have revitalized interest in immunotherapy for metastatic RCC.
    • Phase I/II trials show promising outcomes with monoclonal antibodies targeting the PD-1 receptor and its ligand.

    More Related Videos

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.9K
    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
    11:08

    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

    Published on: February 14, 2025

    2.0K

    Related Experiment Videos

    Last Updated: Mar 29, 2026

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.4K
    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.9K
    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
    11:08

    Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

    Published on: February 14, 2025

    2.0K

    Impact:

    • Immunotherapy, particularly checkpoint inhibitors, represents a paradigm shift in RCC treatment.
    • Further research and comparative studies are crucial to establish immunotherapy's role against standard therapies.
    • This review highlights the growing efficacy and future directions of immunotherapy in managing advanced renal cell carcinoma.